Allarity Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Allarity Therapeutics (ALLR).

Price Target Range — 4 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$11Upside to Avg. PT+1178.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 16, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$10→$11
Jun 8, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$10→$10
Apr 10, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$10→$10
Dec 9, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$9→$10
Sep 26, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$9→$9
Jul 28, 2025	Ascendiant Capital	Edward Woo	Initiate	Buy	$9

More with Benzinga EdgeGet Access

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.75 to $10.25.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.5 to $9.75.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target from $9 to $9.25.

Benzinga Newsdesk

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Avi Kapoor

Allarity Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Allarity Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

People Also Watch

People Also Watch

Allarity Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Allarity Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

PROAscendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

PROAscendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

PROAscendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

PROAscendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25

This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

PRO
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25